

Alyssa R Golden

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3251629/publications.pdf>

Version: 2024-02-01

28
papers

1,454
citations

586496

16
h-index

536525

29
g-index

29
all docs

29
docs citations

29
times ranked

1900
citing authors

#	ARTICLE	IF	CITATIONS
1	Activity of cefepime/taniborbactam and comparators against whole genome sequenced ertapenem-non-susceptible Enterobacterales clinical isolates: CANWARD 2007-19. JAC-Antimicrobial Resistance, 2022, 4, dlab197.	0.9	10
2	PCV-15 and PPSV-23 coverage of invasive and respiratory tract <i>Streptococcus pneumoniae</i> , including MDR and XDR isolates: CANWARD 2007-20. Journal of Antimicrobial Chemotherapy, 2022, 77, 1444-1451.	1.3	2
3	Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria. Drugs, 2022, 82, 533-557.	4.9	12
4	Comparison of PCV-10 and PCV-13 vaccine coverage for invasive pneumococcal isolates obtained across Canadian geographic regions, SAVE 2011 to 2017. Diagnostic Microbiology and Infectious Disease, 2021, 99, 115282.	0.8	7
5	Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia. Drugs, 2021, 81, 233-256.	4.9	20
6	ESBL-positive <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> isolates from across Canada: CANWARD surveillance study, 2007-18. Journal of Antimicrobial Chemotherapy, 2021, 76, 2815-2824.	1.3	8
7	Comparison of phenotypic antimicrobial susceptibility testing results and WGS-derived genotypic resistance profiles for a cohort of ESBL-producing <i>Escherichia coli</i> collected from Canadian hospitals: CANWARD 2007-18. Journal of Antimicrobial Chemotherapy, 2021, 76, 2825-2832.	1.3	4
8	In vitro activity of imipenem-relebactam against various resistance phenotypes/genotypes of Enterobacterales and <i>Pseudomonas aeruginosa</i> isolated from patients across Canada as part of the CANWARD study, 2016-2019. Diagnostic Microbiology and Infectious Disease, 2021, 101, 115418.	0.8	8
9	Whole genome characterization of <i>Streptococcus pneumoniae</i> from respiratory and blood cultures collected from Canadian hospitals before and after PCV-13 implementation in Canada: Focus on serotypes 22F and 33F from CANWARD 2007-2018. Vaccine, 2021, 39, 5474-5483.	1.7	6
10	Use of Fosfomycin Etest To Determine <i>In Vitro</i> Susceptibility of Clinical Isolates of <i>Enterobacterales</i> Other than <i>Escherichia coli</i> , Nonfermenting Gram-Negative Bacilli, and Gram-Positive Cocci. Journal of Clinical Microbiology, 2021, 59, e0163521.	1.8	7
11	Invasive pneumococcal disease caused by serotypes 22F and 33F in Canada: the SAVE study 2011-2018. Diagnostic Microbiology and Infectious Disease, 2021, 101, 115447.	0.8	7
12	Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. Drugs, 2020, 80, 285-313.	4.9	60
13	In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units. Diagnostic Microbiology and Infectious Disease, 2020, 97, 115012.	0.8	36
14	Trends in antimicrobial resistance over 10 years among key bacterial pathogens from Canadian hospitals: results of the CANWARD study 2007-16. Journal of Antimicrobial Chemotherapy, 2019, 74, iv22-iv31.	1.3	16
15	Comparison of antimicrobial resistance patterns in <i>Streptococcus pneumoniae</i> from respiratory and blood cultures in Canadian hospitals from 2007-16. Journal of Antimicrobial Chemotherapy, 2019, 74, iv39-iv47.	1.3	21
16	42936 pathogens from Canadian hospitals: 10 years of results (2007-16) from the CANWARD surveillance study. Journal of Antimicrobial Chemotherapy, 2019, 74, iv5-iv21.	1.3	43
17	Antimicrobial-resistant pathogens in Canadian ICUs: results of the CANWARD 2007 to 2016 study. Journal of Antimicrobial Chemotherapy, 2019, 74, 645-653.	1.3	26
18	Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Drugs, 2019, 79, 271-289.	4.9	274

#	ARTICLE	IF	CITATIONS
19	Imipenemâ€“Relebactam and Meropenemâ€“Vaborbactam: Two Novel Carbapenem-Î²-Lactamase Inhibitor Combinations. <i>Drugs</i> , 2018, 78, 65-98.	4.9	291
20	Analysis of multidrug resistance in the predominant <i>Streptococcus pneumoniae</i> serotypes in Canada: the SAVE study, 2011â€“15. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, vii12-vii19.	1.3	48
21	Molecular characterization of predominant <i>Streptococcus pneumoniae</i> serotypes causing invasive infections in Canada: the SAVE study, 2011â€“15. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, vii20-vii31.	1.3	27
22	Antimicrobial susceptibility testing of invasive isolates of <i>Streptococcus pneumoniae</i> from Canadian patients: the SAVE study, 2011â€“15. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, vii5-vii11.	1.3	17
23	Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia. <i>Drugs</i> , 2016, 76, 1737-1757.	4.9	38
24	Invasive <i>Streptococcus pneumoniae</i> in Canada, 2011â€“2014: Characterization of new candidate 15-valent pneumococcal conjugate vaccine serotypes 22F and 33F. <i>Vaccine</i> , 2016, 34, 2527-2530.	1.7	28
25	Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. <i>Drugs</i> , 2016, 76, 567-588.	4.9	199
26	Tedizolid: A Novel Oxazolidinone with Potent Activity Against Multidrug-Resistant Gram-Positive Pathogens. <i>Drugs</i> , 2015, 75, 253-270.	4.9	140
27	Assessment of multidrug resistance, clonality and virulence in non-PCV-13 <i>Streptococcus pneumoniae</i> serotypes in Canada, 2011-13. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1960-4.	1.3	31
28	Characterization of MDR and XDR <i>Streptococcus pneumoniae</i> in Canada, 2007â€“13. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2199-2202.	1.3	65